Offering a choice of HIV prevention options to young people in rural South Africa
Tests choice of long-acting or daily oral HIV prevention in 15 to 30 year olds.
Key facts
- Who runs it
- Africa Health Research Institute
- Where
- Somkele, South AfricaSee the site
- Trial code
- Registry title
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,052 people, planned
- Started
- 27 Feb 2024
- Planned end
- Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- APRETUDE (cabotegravir) 600 mg\3 mL
- DAPIRING (Dapivirine) 25mg Vaginal Ring
- tenofovir disoproxil and emtricitabine
- Tenofovir Disoproxil, Lamuvidine and Dolutegravir
- Record updated
- 9 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young men and women aged 15-30 in rural South Africa who use community sexual and reproductive health services and have a documented HIV-negative test.
- Age
- 15 to 30 years
- Sex
- Men and women
- Earlier treatment
- People who are already on PrEP can join. They must also be able to take PrEP.
- Biomarker or test result
- A documented HIV-negative test.
Main reasons for not taking part
- Allergy to the study drugs or their parts
- The investigator judges the person not able to join
- Weight of 35 kg (77 lb) or less
- CAB LA: taking certain contraindicated medicines, severe mental health disorder, hepatitis B surface antigen positive, untreated hepatitis C, or abnormal liver tests
- Dapivirine ring: pregnancy
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- All young men and women aged 15-30 who are residing in the 40 administrative clusters in the study district and attend any integrated SRH/HIV service
- Documented HIV negative test
- Suitable for PrEP and/or already on PrEP
- Weight > 35 kg
- Understand the required dosing schedule and HIV testing
- Aware that details can be shared with a peer navigator to support their follow-up
- If pregnant or breast feeding and/or planning to become pregnant participant can be offered CAB LA, if risk of acquiring HIV out weighs unknown risk of CAB LA, but must understand that safety in pregnancy or breast feeding for CAB LA has not been established and oral daily PrEP is a safe alternative
Who cannot take part
- History or presence of allergy to the study drugs or their components
- CAB LA: Taking medication that is contraindicated (Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, Rifampin, rifapentine) and Severe mental health disorder, Hep B surface antigen positive, living with hepatitis C and not yet treated, or abnormal liver function tests (ALT more than two times the upper limit of normal)
- Investigator assessment find them not suitable
- Additional exclusion criteria for specific products:
- DapiRing: Pregnancy
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 15 and 30 years old?
This trial is currently available in South Africa.
- Africa Health Research InstituteSomkele, South AfricaContact: Maryam Shahmanesh, PhDTaking people
About the trial
What the trial wants to find out
The goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retention, and population prevalence of sexually transmissible HIV amongst adolescents and young adults living in rural South Africa.
Read full original descriptionShow less
Researchers will compare adding the choice of long-acting PrEP, i.e. two monthly injectable cabotegravir (CAB LA) or dapiravine vaginal ring and HIV post exposure prophylaxis packs to daily oral PrEP integrated with community-based SRH in the 20 intervention clusters with standard of care (SoC), daily oral PrEP integrated with community-based SRH in the 20 control clusters, on uptake and retention on PrEP. We hypothesise that offering a choice of long-acting or oral PrEP and PEP within the community-based delivery of SRH services will overcome the challenges and barriers to effective use of oral daily PrEP and lead to a population-level effect on uptake and retention on PrEP and thus the prevalence of sexually transmissible HIV amongst 15-30 year olds living in rural KwaZulu-Natal, South Africa.
The 2 groups in the trial
- Intervention: Choice of long-acting PrEP and PEP added to Thetha Nami ngithethe naweTreatment being tested
Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including a choice of effective PrEP or PEP. At the mobile AYFS in the intervention clusters nurses will offer the choice of either daily oral tenofovir/emtricitabine or injectable long acting cabotegravir (CAB LA) to be delivered to adolescents and young adults at risk of HIV acquisition. Those who decline will have the option of three monthly dapivarine vaginal rings or Post Exposure Prophylaxis (PEP) packs (tenofovir/lamuvidine/dolutegravir) to take home. Peer navigators will promote long-acting PrEP in addition to oral PrEP. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits.
Treatment: APRETUDE (cabotegravir) 600 mg\3 mL, DAPIRING (Dapivirine) 25mg Vaginal Ring, tenofovir disoproxil and emtricitabine, and Tenofovir Disoproxil, Lamuvidine and Dolutegravir
- Control (Enhanced SoC): Thetha Nami ngithethe naweExisting treatment, for comparison
Tailored peer-led psychosocial support and social mobilisation into community based SRH and differentiated HIV care and prevention, including oral tenofovir/emtricitabine PrEP. In the mobile AYFS, young people are offered self-taken vaginal swabs or urine testing for sexually transmitted infections (STIs), family planning support and syndromic and aetiological management for STIs; HIV counselling and two POCT; immediate initiation of ART if living with HIV and oral tenofovir/emtricitabine PrEP if HIV test is negative and they are suitable. Peer navigators in control clusters will promote oral PrEP during their community based health promotion activities. As part of the peer mentorship package, the peer naviators will remind young people of their follow-up visits and if required accompany young people to the mobile clinics.
Treatment: tenofovir disoproxil and emtricitabine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation
- Plain-language title
- Offering a choice of HIV prevention options to young people in rural South AfricaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06250504, who can take part
- Publications
- Record updated
- 9 July 2026